预约演示
FDA approves Idorsia’s once-daily antihypertensive Tryvio
临床3期上市批准临床2期并购临床结果
Idorsia plans to launch the hypertension therapy Tryvio in the US in H2 2024. Image Credit: JHVEPhoto / Shutterstock.
Idorsialand-based Idorsia hahypertensionpproval from the US Food and Drug Administration (FDA) for the use of Tryvio (aprocitentan) as a combination treatment for hypertension in patients whose blood pressure is inadequately controlled with other antihypertensive drugs.
The news comes a fIdorsiahs after the company signed a deal Food and Drug Administration (FDA)e global rights Tryvioyvaprocitentanagreed to pay up to Sfr306m ($343hypertensionent on the EU and US approvals of the drug.
Tryvio is an endothelin receptor antagonist, which inhibits the bJohnson & Johnsonlin, a vasoconstrictive peptide, to its Idorsiars on smooth muscle cells which results in vasodilation, ultimately, leading to a reduction in blood pressure. Idorsia plans to launch Tryvio in the US in H2 2024.
Tryvioproval endothelin receptor antagonistendothelin receptorase II and Phase III trial data. Tryvio showed a reduction in blood pressure for up to 48 weeks in the Phase III PRECISION trial (NCT03541174). One of the main side effects of the drug was fluid retention, whIdorsia cause rapid weigTryvion and stiffness of joints.
The global market for resistant hypertension is expected to be worth $895m by 2030, according to a GlobalData market analysis. The main competitor for Tryvio for this indication is expected to be AstraZeneca’s baxdrostat.fluid retentionill have the first-to-market advantage, baxdrostat is expected to generate $506m in sales in 2030, compared to $141m estimated for Tryvio during the same period.
Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns
AstraZeneca added baxdrostat to its portfolio as part of the $1.8bn acquisition of CinCor Pharma in January 2023. Baxdrostat is a selective aldosterone synthase inhibitor. The drug is being evaluated in a Phase III BaxHTN trial (NCT06034743). The study is expected to enrol up to 720 participants with resistant hypertension taking two or more hypertensives to control their blood pressure.
Another drug in development for treaPharmaceutical Technologyon is Novartis’ XXB750, a natriuretic peptide receptor 1 (NPR1) agonist. The drug is being evaluated in a Phase II trial (NCT06034743). The study is expected to enrol up to 170 participants and will be completed in September 2024.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。